FGFR1 Fusion

CI-VAR-00001187Explore in graph →CIViC 569

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia2
v::FGFR1 Fusion	Sorafenib + SunitinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7375 In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 · Open in CIViC	civic
v::FGFR1 Fusion	Sunitinib	Predictive	D	Does Not Support Sensitivity Response	3	rejected	EID7376 In a preclinical trial, KG1 AML cell lines with the FGFR1OP2-FGFR1 fusion mutation were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more e… (full text at CIViC) PMID 21482694 · Gozgit et al., 2011 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Chronic Myelomonocytic Leukemia1
v::FGFR1 Fusion	(diagnostic)	Diagnostic	A	Supports Negative	5	accepted	EID1427 The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusi… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic

Hematopoietic and Lymphoid Cell Neoplasm1
v::FGFR1 Fusion	(diagnostic)	Diagnostic	A	Supports Positive	5	accepted	EID1435 The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated wit… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic

Malignant Neoplasm1
FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion	Fexagratinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11675 In this NCI-MATCH trial subprotocol W, 48 patients harbouring FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n=19), or FGFR1 or FGFR3 fusions (n=9) were treated with… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic